Synergistic antitumor effects of combination treatment with metronomic doxorubicin and VEGF-targeting RNAi nanoparticles

Gijung Kwak, Sung Duk Jo, Dongkyu Kim, Hyosuk Kim, Myung Goo Kim, Kwangmeyung Kim, Ick Chan Kwon, Sun Hwa Kim

Research output: Contribution to journalArticlepeer-review

36 Citations (Scopus)


Conventional cancer treatment strategies have been aimed at eradicating all cancer cells. To this end, standard chemotherapeutic approaches have relied on the maximum tolerated dose (MTD) of cytotoxic drugs with a long off-therapy interval, leading to heavy toxic side effects accompanied by drug resistance. To avoid the problems associated with the traditional MTD chemotherapy, metronomic chemotherapy with relatively low dose continuous treatments of cytotoxic drugs has been proposed as an alternative to the predominant paradigm of directly killing all cancer cells. Low-dose metronomic (LDM) chemotherapy is expected to have not only antitumor effects without toxicity and drug resistance, but also beneficial anti-angiogenic effects by causing selective apoptosis of tumor endothelial cells. In an attempt to keep the drug resistance under control and halt exponential tumor growth, herein, we combined LDM chemotherapy with a second anti-angiogenic strategy. The selective blockade of vascular endothelial growth factor (VEGF) in combination with metronomic doxorubicin (Dox) induced synergistic antitumor effects mainly through an antiangiogenic mechanism. For specific VEGF suppression, VEGF-targeting siRNA was delivered to tumor tissue using polymerized siRNA/thiolated glycol chitosan (poly-siVEGF/tGC) nanoparticles, leading to efficient VEGF gene knockdown in tumor tissue with a sequence-specific manner. Although the single treatment with metronomic Dox and poly-siVEGF/tGC nanoparticles alone showed some antitumor activity, notably, the combination of the two therapies resulted in superb tumor regression without causing systemic toxicity or drug resistance. Thus, these results suggest that the VEGF-targeted RNAi using poly-siRNA/tGC nanoparticles in combination with LDM chemotherapy could be a promising synergistic strategy for controlling tumor growth by enhancing the efficacy of anti-angiogenesis while minimizing toxicity and drug resistance.

Original languageEnglish
Pages (from-to)203-213
Number of pages11
JournalJournal of Controlled Release
Publication statusPublished - 2017 Dec 10

Bibliographical note

Funding Information:
This research was supported by Global Innovative Research Center (GiRC) Program [ NRF-2012K1A1A2A01056095 ] and Creative Materials Discovery Program [ NRF-2016M3D1A1021392 ] through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and Future Planning ; and the Intramural Research Program of KIST .

Publisher Copyright:
© 2017 Elsevier B.V.

Copyright 2018 Elsevier B.V., All rights reserved.


  • Anti-angiogenesis
  • Combination therapy
  • Drug resistance
  • Low-dose metronomic chemotherapy
  • VEGF
  • siRNA

ASJC Scopus subject areas

  • Pharmaceutical Science


Dive into the research topics of 'Synergistic antitumor effects of combination treatment with metronomic doxorubicin and VEGF-targeting RNAi nanoparticles'. Together they form a unique fingerprint.

Cite this